1. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial

   • Theodore F. Logan
   • Fayega Jadali
   • Candace Johnson

   Original Article Pages: 433 - 444

2. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat

   • Jing Liu
   • Eric H. Kraut
   • Kenneth K. Chan

   Original Article Pages: 445 - 453

3. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver

   • Shogo Ozawa
   • Masashi Hamada
   • Yasuo Ohno

   Original Article Pages: 454 - 458

4. The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer

   • Jean-Marc Ferrero
   • Emmanuel Chamorey
   • Gérard Milano

   Original Article Pages: 459 - 464

5. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

   • James P. Thomas
   • Kendra D. Tutsch
   • George Wilding

   Original Article Pages: 465 - 472

6. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518

   • Mirjam Crul
   • Laurens V. Beerepoot
   • Jan H. Schellens

   Original Article Pages: 473 - 478

7. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

   • Ioannis A. Avramis
   • Garyfallia Christodoulopoulos
   • Vassilios I. Avramis

   Original Article Pages: 479 - 489

8. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts

   • Henriette Gourdeau
   • Philippe Genne
   • Giorgio Attardo

   Original Article Pages: 490 - 496

9. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

   • Jorge Cortes
   • Apostolia M. Tsimberidou
   • Francis J. Giles

   Original Article Pages: 497 - 500

10. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice

    • Maria V. Papadopoulou
    • Ming Ji
    • Melinda G. Hollingshead

    Original Article Pages: 501 - 508

11. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925

    • Patricia E. Schroeder
    • Brian B. Hasinoff

    Original Article Pages: 509 - 513

12. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule

    • Nadja E. Schoemaker
    • Ron A. Mathôt
    • Jos H. Beijnen

    Short Communication Pages: 514 - 517